Featured Company /
NurExone Biologic Inc.
An estimated 250,000-500,000 people experience a Spinal Cord Injury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined to a wheelchair. What if there were a way to repair the damaged tissue and allow those people to once again have feeling and regain use of their limbs? Thanks to tiny particles known as exosomes, such a miracle may be on the horizon.
Exosomes are small extracellular vesicles that are secreted by all Stem Cell types. They are thought to play a role in cell-to-cell communication.
Exosomes contain a variety of proteins, lipids, and nucleic acids, and have diverse potential in emerging technologies to address areas of unmet medical need. Exosomes can be used to deliver drugs, genes, and other molecules to target cells, making them ideal for new therapeutics and improving existing drugs. Plus, they also can function as potential biomarkers, giving them unique value in diagnostics applications. It’s not hyperbole that exosomes may revolutionize many standards of care and provide people hope in diseases fraught with desperation.
Every year, thousands of people are relegated to wheelchairs because of irreparable spinal cord injuries. Research suggests that exosomes can be used to regenerate damaged tissue and organs.
Further, in addition to being used to deliver drugs to diseased cells, exosomes have also been shown to be effective in reducing inflammation and stimulating the immune system. To wit, it should be unsurprising that exosomes are a rapidly growing field of research.
The buzz around exosomes and their ability to carry payloads from one cell to another has been steadily growing, evidenced by Bio-Techne Corporation (NASDAQ: TECH) agreeing to pay $250 million in cash (and up to $325 million for achieving certain milestones) to acquire Exosome Diagnostics. In 2020, Eli Lilly (NYSE: LLY) (NASDAQ: CAPR) (TSX-Venture: NRX)
Capricor’s StealthX™ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted therapies to treat or prevent a variety of diseases.
NurExone Biologic Inc. (TSX-Venture: NRX) quick explanation video here discussing NurExone's exosome-based therapy.)
With operations launched in 2020, NurExone possesses a lot more fundamental strength than is typically found in such a young company. The company obtained an exclusive worldwide license from the Technion and Tel Aviv University to develop and commercialize an exosome technology that has been under development for 10+ years. NurExone has a global vision and has submitted patent applications in the U.S. and other key markets under the Patent Cooperation Treaty (PCT), with a first U.S. patent awarded in January. The rest of the IP portfolio includes 2 PCTs on Production and Composition of Matter of its exosomes and 4 provisional patents on loading technique and siRNA target sequences.
NurExone operates according to two business lines – Development of a first exosome-based
therapy for acute SCI (spinal cord injuries). In parallel, the company plans to soon monetize its proprietary exosome technology and production platform through licensing to the global biopharmaceutical industry for other diseases and indications.
Get to Know ExoTherapy and ExoPTEN
One of the key assets of NurExone's technology is its drug delivery system, branded ExoTherapy. ExoTherapy is a play on the combination of exosomes with therapeutic compounds. The first ExoTherapy product, which uses modified siRNA as its therapeutic molecule, is called ExoPTEN, which is designed to treat acute spinal cord injuries and has shown promising initial results in preclinical studies for neuron regeneration in rat models.
While very early in development, the data from an internal preclinical study of ExoPTEN were very positive and inspiring. In short, the company used the ExoTherapy platform to produce and load exosomes with pharmaceutical cargo targeting damaged tissue at the core of SCI. Healthy rats with full mobility underwent a complete transection of the spinal cord, rendering their rear legs paralyzed. The rats were then treated with exosomes only (control group) or with intranasal administration of ExoPTEN. NurExone reported positive imaging results visualizing successful nerve regeneration following traumatic full transection of the spinal cord in rats.
These imaging results align with previous functional results showing a remarkable recovery of motor function in 75% of paralyzed rats suffering from spinal cord injuries that were treated with the new therapy. In other words, rats treated with ExoPTEN experienced restored functionality of their legs including sensorial recovery. These results align with previous Proof of Concept experiments (see video here: https://nurexone.com/study-results/ )
The study indicates that ExoPTEN therapy enables new nerve-connections to be made, effectively repairing the transected spinal cord, at least partially. For humans, the research suggests that ExoTherapy may facilitate even a partial recovery, providing patients with a better outcome than had been possible to date. NurExone is aiming for filing an investigational new drug (IND) application during 2024 to initiate clinical trials.
ExoPTEN is differentiated with some competitive advantages. First, it can be administered non-invasively (intranasal). Next, the treatment is off-the-shelf and not personalized, which conquers some of the logistic headaches involved with autologous (derived from patient) therapies. Further, being a novel therapeutic targeting a patient population under 200,000 people, ExoPTEN may be an ideal candidate for an Orphan Drug designation, which expedites development and provides financial incentives to develop a new drug.
According to Grand View Research, the global market for acute spinal cord injury will reach $2.9 billion by 2027.
As for the other business silo, licensing the proprietary exosome production and loading platform to biopharmaceutical companies for a litany of diseases and conditions, Grand View Research estimates the global market for exosome-based diagnostics and therapeutics to reach $2.3 billion by 2030. Broadly, Grand View’s analysts see the global exosomes market size as valued at $112.25 million in 2022 and anticipate it to expand at a compound annual growth rate (CAGR) of 32.75% by 2030.
A Quick Word on an Amazing Team
NurExone management is led by CEO, Dr. Lior Shaltiel, an awarded scientist with extensive multidisciplinary international experience. The company’s team includes experts in biological research and a scientific advisory board led by world renowned Prof. Shulamit Levenberg, and Prof. Nahshon Knoller, the former head of the neurosurgery department in the largest hospital in Israel, that led 3 clinical SCI studies.
The team was further strengthened during the second quarter with the appointment of Dr. Gadi Riesenfeld to the Board of Directors. Dr. Riesenfeld was previously the president of Pharmos Corporation (formerly NASDAQ: PARS) and president of several biopharmaceutical companies, including Kamapharm Ltd., Galisar Ltd., and OticPharma.
This team is skilled clinically and at the negotiating table too. Not only did they secure the licensing rights, but they also recently inked a deal to make their lab better. In June, the company announced a collaboration with Particle Metrix, a leading provider of particle analysis devices. In connection with the collaboration, a highly advanced Nanoparticle Tracking Analysis instrument (NTA) has been placed at the company’s laboratory. Management plans to leverage the capabilities of the advanced NTA to validate its methodology for analysis of loaded exosomes, a vital part of the development process of its ExoPTEN drug.
The company has the cash to keep moving forward following the closing of a second tranche of a non-brokered private placement this month. The financing raised about CAD$1.5 million, enough cash runway to get through the year and into 2024, a time when things will get very interesting as it nears the clinical stage.
About AllPennyStocks.com:
AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders. Outside of the countless free content available to visitors, AllPennyStocks.com Pro (premium service) caters to traders looking for that trading edge by offering monthly stock picks, daily penny stock to watch trade ideas, market commentary and more.
As a result of its commitment to journalistic excellence and abundance of information in a particular area of equity investing (micro-cap investing) where there aren’t many credible sources of information, AllPennyStocks.com continues to have one of the largest audiences of micro-cap investors on the internet.
Corporate Snapshot:
NurExone Biologic Inc.
Stock Symbol:
NRX
Stock Exchange:
TSX-Venture
Sector:
Healthcare
52 Week High:
$0.4300
52 Week Low:
$0.1000
Current Stock Quote / Chart / News: Click here
Information as of
October 04, 2023
An estimated 250,000-500,000 people experience a Spinal Cord Injury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined to a wheelchair. What if there were a way to repair the damaged tissue and allow those people to once again have feeling and regain use of their limbs? Thanks to tiny particles known as exosomes, such a miracle may be on the horizon.
Exosomes are small extracellular vesicles that are secreted by all Stem Cell types. They are thought to play a role in cell-to-cell communication.
Exosomes contain a variety of proteins, lipids, and nucleic acids, and have diverse potential in emerging technologies to address areas of unmet medical need. Exosomes can be used to deliver drugs, genes, and other molecules to target cells, making them ideal for new therapeutics and improving existing drugs. Plus, they also can function as potential biomarkers, giving them unique value in diagnostics applications. It’s not hyperbole that exosomes may revolutionize many standards of care and provide people hope in diseases fraught with desperation.
Every year, thousands of people are relegated to wheelchairs because of irreparable spinal cord injuries. Research suggests that exosomes can be used to regenerate damaged tissue and organs.
Further, in addition to being used to deliver drugs to diseased cells, exosomes have also been shown to be effective in reducing inflammation and stimulating the immune system. To wit, it should be unsurprising that exosomes are a rapidly growing field of research.
The buzz around exosomes and their ability to carry payloads from one cell to another has been steadily growing, evidenced by Bio-Techne Corporation (NASDAQ: TECH) agreeing to pay $250 million in cash (and up to $325 million for achieving certain milestones) to acquire Exosome Diagnostics. In 2020, Eli Lilly (NYSE: LLY) (NASDAQ: CAPR) (TSX-Venture: NRX)
Capricor’s StealthX™ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted therapies to treat or prevent a variety of diseases.
NurExone Biologic Inc. (TSX-Venture: NRX) quick explanation video here discussing NurExone's exosome-based therapy.)
With operations launched in 2020, NurExone possesses a lot more fundamental strength than is typically found in such a young company. The company obtained an exclusive worldwide license from the Technion and Tel Aviv University to develop and commercialize an exosome technology that has been under development for 10+ years. NurExone has a global vision and has submitted patent applications in the U.S. and other key markets under the Patent Cooperation Treaty (PCT), with a first U.S. patent awarded in January. The rest of the IP portfolio includes 2 PCTs on Production and Composition of Matter of its exosomes and 4 provisional patents on loading technique and siRNA target sequences.
NurExone operates according to two business lines – Development of a first exosome-based
therapy for acute SCI (spinal cord injuries). In parallel, the company plans to soon monetize its proprietary exosome technology and production platform through licensing to the global biopharmaceutical industry for other diseases and indications.
Get to Know ExoTherapy and ExoPTEN
One of the key assets of NurExone's technology is its drug delivery system, branded ExoTherapy. ExoTherapy is a play on the combination of exosomes with therapeutic compounds. The first ExoTherapy product, which uses modified siRNA as its therapeutic molecule, is called ExoPTEN, which is designed to treat acute spinal cord injuries and has shown promising initial results in preclinical studies for neuron regeneration in rat models.
While very early in development, the data from an internal preclinical study of ExoPTEN were very positive and inspiring. In short, the company used the ExoTherapy platform to produce and load exosomes with pharmaceutical cargo targeting damaged tissue at the core of SCI. Healthy rats with full mobility underwent a complete transection of the spinal cord, rendering their rear legs paralyzed. The rats were then treated with exosomes only (control group) or with intranasal administration of ExoPTEN. NurExone reported positive imaging results visualizing successful nerve regeneration following traumatic full transection of the spinal cord in rats.
These imaging results align with previous functional results showing a remarkable recovery of motor function in 75% of paralyzed rats suffering from spinal cord injuries that were treated with the new therapy. In other words, rats treated with ExoPTEN experienced restored functionality of their legs including sensorial recovery. These results align with previous Proof of Concept experiments (see video here: https://nurexone.com/study-results/ )
The study indicates that ExoPTEN therapy enables new nerve-connections to be made, effectively repairing the transected spinal cord, at least partially. For humans, the research suggests that ExoTherapy may facilitate even a partial recovery, providing patients with a better outcome than had been possible to date. NurExone is aiming for filing an investigational new drug (IND) application during 2024 to initiate clinical trials.
ExoPTEN is differentiated with some competitive advantages. First, it can be administered non-invasively (intranasal). Next, the treatment is off-the-shelf and not personalized, which conquers some of the logistic headaches involved with autologous (derived from patient) therapies. Further, being a novel therapeutic targeting a patient population under 200,000 people, ExoPTEN may be an ideal candidate for an Orphan Drug designation, which expedites development and provides financial incentives to develop a new drug.
According to Grand View Research, the global market for acute spinal cord injury will reach $2.9 billion by 2027.
As for the other business silo, licensing the proprietary exosome production and loading platform to biopharmaceutical companies for a litany of diseases and conditions, Grand View Research estimates the global market for exosome-based diagnostics and therapeutics to reach $2.3 billion by 2030. Broadly, Grand View’s analysts see the global exosomes market size as valued at $112.25 million in 2022 and anticipate it to expand at a compound annual growth rate (CAGR) of 32.75% by 2030.
A Quick Word on an Amazing Team
NurExone management is led by CEO, Dr. Lior Shaltiel, an awarded scientist with extensive multidisciplinary international experience. The company’s team includes experts in biological research and a scientific advisory board led by world renowned Prof. Shulamit Levenberg, and Prof. Nahshon Knoller, the former head of the neurosurgery department in the largest hospital in Israel, that led 3 clinical SCI studies.
The team was further strengthened during the second quarter with the appointment of Dr. Gadi Riesenfeld to the Board of Directors. Dr. Riesenfeld was previously the president of Pharmos Corporation (formerly NASDAQ: PARS) and president of several biopharmaceutical companies, including Kamapharm Ltd., Galisar Ltd., and OticPharma.
This team is skilled clinically and at the negotiating table too. Not only did they secure the licensing rights, but they also recently inked a deal to make their lab better. In June, the company announced a collaboration with Particle Metrix, a leading provider of particle analysis devices. In connection with the collaboration, a highly advanced Nanoparticle Tracking Analysis instrument (NTA) has been placed at the company’s laboratory. Management plans to leverage the capabilities of the advanced NTA to validate its methodology for analysis of loaded exosomes, a vital part of the development process of its ExoPTEN drug.
The company has the cash to keep moving forward following the closing of a second tranche of a non-brokered private placement this month. The financing raised about CAD$1.5 million, enough cash runway to get through the year and into 2024, a time when things will get very interesting as it nears the clinical stage.
About AllPennyStocks.com:
AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders. Outside of the countless free content available to visitors, AllPennyStocks.com Pro (premium service) caters to traders looking for that trading edge by offering monthly stock picks, daily penny stock to watch trade ideas, market commentary and more.
As a result of its commitment to journalistic excellence and abundance of information in a particular area of equity investing (micro-cap investing) where there aren’t many credible sources of information, AllPennyStocks.com continues to have one of the largest audiences of micro-cap investors on the internet.
Forward Looking Statements
This report includes forward-looking statements that reflect current expectations about its future results, performance, prospects and opportunities. NurExone Biologic Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause NurExone Biologic Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.
Disclaimer
AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for NurExone Biologic Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.
© 1999-2024AllPennyStocks.com Media, Inc. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views; opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in its disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site.
AllPennyStocks.com has been compensated thirty-seven thousand five hundred dollars by a third-party for its efforts in presenting the NRX profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "expects", "will," "anticipates," "estimates, "believes," or that by statements indicating certain actions "may," "could," or "might" occur.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
